Form 4 for RGEN REPLIGEN CORP
Accepted 2023-05-22 00:00:00 ET · period of report 2023-05-18 · accession 0000899243-23-013671 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-22 | 2023-05-18 | RGEN | DAWES KAREN A | Dir | A - Grant | $0.00 | +798 | 77.2K | +1% | $0 |
| D | 2023-05-22 | 2023-05-18 | RGEN | DAWES KAREN A | Dir | A - Grant | $0.00 | +1,730 | 1,730 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-18 | A | A | 798 | $0.00 | 77,199 | D | — | — | (F1) Ms. Dawes was awarded 798 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 18, 2024, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-05-18 | A | A | 1,730 | $0.00 | 1,730 | D | $156.63 · 2024-05-18 to 2033-05-18 | 1,730 Common Stock | (F2) Award vests in full on the earlier of May 18, 2024, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. |